Healthcare providers may prescribe Cinryze to prevent sudden episodes of swelling that occur in people who have a rare genetic disorder called hereditary angioedema (HAE). Cinryze is used to reduce swelling that occurs when fluid leaks from the veins during an HAE attack. This medicine is approved for adults and teenagers as young as 13 years old.
Cinryze® (C1 esterase inhibitor) is a prescription medication approved to prevent attacks of angioedema (sudden swelling in the deep layers of the skin) in adults and teenagers with a condition known as hereditary angioedema (HAE). It belongs to a class of drugs known as C1 inhibitors.
Hereditary angioedema is a rare genetic condition characterized by sudden, rapid swelling of the body. The majority of cases are passed down through families; however, in some people, there is no evidence of a family history.
Swelling associated with HAE can occur in various areas of the body, including the hands, feet, face, genitals, upper airways, larynx (voice box), and abdomen (stomach). People with this condition usually first experience swelling in their childhood, with symptoms becoming more severe around the onset of puberty.
The frequency of attacks varies considerably from person to person, and can even vary among people in the same family. In addition, the severity of symptoms can vary from attack to attack and from person to person. Attacks are usually self-limiting, typically lasting from two to five days. However, attacks can also be life-threatening.
HAE attacks are associated with considerable symptoms. Swelling of the hands and feet can be quite painful, preventing people from performing their normal daily activities. Attacks involving the stomach or intestines can also lead to significant pain as well as nausea, vomiting, diarrhea, and dehydration. Swelling of the throat can close off the airway and lead to suffocation and death.
Cinryze is used as routine prophylaxis, which means it is used regularly to prevent HAE attacks from occurring. It is given every three to four days as an injection into a vein (an intravenous, or IV, injection). The medication may be administered by a healthcare provider or, after adequate training, self-injected.